Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05589974

Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy

Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Stavanger University Hospital, Department of Ophthalmology

Stavanger, 4016, Norway

Location status: Recruiting

Location contact

Vegard Forsaa, MD

CONTACT

[email protected]

+47 48152212

Vegard Forsaa, PhD

PRINCIPAL_INVESTIGATOR

About this study

Acute CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics are related to the eventual resolution of subretinal fluid. Such relation can shed light on pathophysiological disease mechanisms and constitute a biomarker for disease activity.

Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-

  • Able to sign informed consent
  • Possible to obtain fundus imaging
  • Acute CSC ˂4 months of duration in one eye, defined as:
  • Subfoveal presence of SRF on OCT
  • Present attack is 1st -3rd attack of CSC

b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT

  • Chronic CSC ≥4 months of duration in one eye, defined as:
  • Subfoveal presence of SRF on OCT
  • Subjective visual loss/symptoms
  • Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT
  • Patient history and examination consistent with chronic CSC

Exclusion criteria

  • History of retinal disease other than CSC (e.g. retinal detachment)
  • Contraindications for FA, ICGA or PDT (only for chronic CSC)

Treatment and study plan

Verteporfin

Drug

Chronic CSC are receiving one treatment before the observation period.

Primary outcomes

  1. Change in mean blur rate

    Time frame: 6 months

    Relative changes in choroidal blood flow

  2. Change in pulse wave form analysis

    Time frame: 6 months

    Changes in the shapes of pulse curves

Secondary outcomes

  1. Change in choroidal density

    Time frame: 6 months

    Changes in the tissue density

  2. Change in choroidal thickness

    Time frame: 6 months

    Changes in the morphology of the choroid

Study contacts

Contact information is provided by the study sponsor or research team.

Vegard Forsaa, MD PhD

CONTACT

[email protected]

+4748152212

Sponsors and collaborators

Lead sponsor

Helse Stavanger HF

Other Gov

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Oct 21, 2022
Registry last updated
Mar 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.